Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2023, Vol. 55 ›› Issue (6): 958-965. doi: 10.19723/j.issn.1671-167X.2023.06.002

Previous Articles     Next Articles

Significance of anti-Jo-1 antibody's clinical stratification in idiopathic inflammatory myopathy and disease spectrum

Jia-chen LI1,Zhan-hong LAI1,Miao SHAO1,Yue-bo JIN1,Xiao-juan GAO2,Ke ZHANG3,Jing HOU4,Yan-ying ZHANG5,Zhan-guo LI1,*(),Yu-hui LI1,*()   

  1. 1. Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China
    2. Department of Rheumatology and Immunology, Ningde Hospital Affiliated to Ningde Normal University, Ningde 352199, Fujian, China
    3. Department of Endocrinology, 80th Group Army Hospital of Chinese PLA, Weifang 261000, Shandong, China
    4. Department of Nephrology, Zhangjiakou First Hospital, Zhangjiakou 075041, Hebei, China
    5. Department of Rheumatology, Shenzhen Hospital of Traditional Chinese Medicine, Shenzhen 518033, China
  • Received:2023-08-19 Online:2023-12-18 Published:2023-12-11
  • Contact: Zhan-guo LI,Yu-hui LI E-mail:li99@bjmu.edu.cn;liyuhui84@163.com
  • Supported by:
    the National Natural Science Foundation of China(82371804);Beijing Natural-Science Foundation(L222017);Peking University People's Hospital Research and Development Foundation(RDX2023-03)

RICH HTML

   

PDF (PC)

Abstract:

Objective: To investigate the significance of anti-histidyl tRNA synthetase (Jo-1) antibody in idiopathic inflammatory myopathies (IIM) and its diseases spectrum. Methods: We enrolled all the patients who were tested positive for anti-Jo-1 antibody by immunoblotting in Peking University People's Hospital between 2016 and 2022. And the patients diagnosed with anti-synthetase antibody syndrome (ASS) with negative serum anti-Jo-1 antibody were enrolled as controls. We analyzed the basic information, clinical characteristics, and various inflammatory and immunological indicators of the patients at the onset of illness. Results: A total of 165 patients with positive anti-Jo-1 antibody were enrolled in this study. Among them, 80.5% were diagnosed with connective tissue disease. And 57.6% (95/165) were diagnosed with IIM, including ASS (84/165, 50.9%), immune-mediated necrotizing myopathy (7/165, 4.2%) and dermatomyositis (4/165, 2.4%). There were 23.0% (38/165) diagnosed with other connective tissue disease, mainly including rheumatoid arthritis (11/165, 6.7%), undifferentiated connective tissue disease (5/165, 3.0%), interstitial pneumonia with autoimmune features (5/165, 3.0%), undifferentiated arthritis (4/165, 2.4%), Sjögren's syndrome (3/165, 1.8%), systemic lupus erythematosus (3/165, 1.8%), systemic vasculitis (3/165, 1.8%), and so on. Other cases included 3 (1.8%) malignant tumor patients, 4 (2.4%) infectious cases and so on. The diagnoses were not clear in 9.1% (15 /165) of the cohort. In the analysis of ASS subgroups, the group with positive serum anti-Jo-1 antibody had a younger age of onset than those with negative serum anti-Jo-1 antibody (49.9 years vs. 55.0 years, P=0.026). Clinical manifestations of arthritis (60.7% vs. 33.3%, P=0.002) and myalgia (47.1% vs. 22.2%, P=0.004) were more common in the ASS patients with positive anti-Jo-1 antibody. With the increase of anti-Jo-1 antibody titer, the incidence of the manifestations of arthritis, mechanic hands, Gottron sign and Raynaud phenomenon increased, and the proportion of abnormal creatine kinase and α-hydroxybutyric dehydrogenase index increased in the ASS patients. The incidence of myalgia and myasthenia were significantly more common in this cohort when anti-Jo-1 antibody-positive ASS patients were positive for one and more myositis specific antibodies/myositis associated autoantibodies (P < 0.05). Conclusion: The disease spectrum in patients with positive serum anti-Jo-1 antibody includes a variety of diseases, mainly ASS. And anti-Jo-1 antibody can also be found in many connective tissue diseases, malignant tumor, infection and so on.

Key words: Anti-histidyl tRNA synthetase antibody, Anti-synthetase syndrome, Connective tissue disease

CLC Number: 

  • R593.2

Figure 1

Disease distribution in patients with positive anti-Jo-1 antibody ASS, anti-synthetase syndrome; IMNM, immune-mediated necrotizing myositis; DM, dermatomyositis; RA, rheumatoid arthritis; UCTD, undifferentiated connective tissue disease; IPAF, interstitial pneumonia with autoimmune features; UA, undifferentiated arthritis; SS, Sjögren's syndrome; SLE, systemic lupus erythematosus; SV, systemic vasculitis; SSc, systemic sclerosis; APS, antiphospholipid syndrome; PMR, polymyalgia rheumatica; Non-CTD, non-connective tissue disease."

Table 1

Comparison of clinical features and laboratory data in ASS with positive and negative anti-Jo-1 antibody"

Items Anti-Jo-1 (+) (n=84) Anti-Jo-1 (-) (n=45) t/Z/χ2 P
Clinical features
  Age of onset/years 49.9±12.8 55.0±11.9 2.247 0.026
  Female 64 (76.2) 33 (73.3) 0.128 0.720
  ILD 72 (85.7) 43 (95.6) 2.933 0.087
  Arthritis 51 (60.7) 15 (33.3) 8.792 0.003
  Myalgia 40 (47.1) 10 (22.2) 7.962 0.005
  Myasthenia 45 (53.6) 21 (46.7) 0.559 0.455
  Dysphagia 5 (6.0) 6 (13.3) 2.047 0.153
  Mechanic hands 45 (53.6) 23 (51.1) 0.071 0.790
  Gottron sign 68 (81.0) 39 (86.7) 0.676 0.411
  Raynaud phenomenon 11 (13.1) 8 (17.8) 0.842 0.474
  Neurologic abnormality 4 (4.8) 0 0.297a
  Malignancy 2 (2.4) 1 (2.2) >0.999a
Laboratory data
  ANA+ 44 (52.4) 29 (64.4) 1.736 0.188
  Anti-Ro-52 (+) 63 (75.0) 36 (80.0) 0.410 0.522
  Anti-PM-Scl 75/100 (+) 5 (6.0) 0 0.156a
  Anti-Mi-2 (+) 2 (2.4) 1 (2.2) >0.999a
  Anti-SAE (+) 1 (1.2) 0 >0.999a
  Anti-MDA5 (+) 1 (1.2) 0 >0.999a
  Anti-NXP2 (+) 0 0
  Anti-TIF-1γ (+) 0 1 (2.2) 0.349a
  Anti-SRP (+) 1 (1.2) 0 >0.999a
  ESR/(mm/h) 20.0 (8.0, 44.0) 32.0 (16.0, 58.0) -2.067 0.039
  Elevated ESR 42 (50.0) 32 (71.1) 5.340 0.021
  CRP/(mg/L) 4.3 (0.6, 27.0) 13.2 (1.5, 27.0) -1.648 0.099
  Elevated CRP 51 (60.7) 24 (53.3) 0.656 0.418
  CK/(U/L) 230.0 (93.0, 1 059.0) 131.0 (69.0, 413.0) -1.733 0.083
  Elevated CK 46 (54.8) 19 (42.2) 1.843 0.175

Figure 2

The top five diseases with high, median and low anti-Jo-1 antibody titer Abbreviations as in Figure 1 and Table 1."

Table 2

Correlation analysis between anti-Jo-1 antibody titer and clinical features and laboratory data of ASS patients"

Items Anti-Jo-1 (+) (n=15) Anti-Jo-1 (++) (n=15) Anti-Jo-1 (+++)(n=54) r P
Clinical features
  Fever 5 (33.3) 4 (26.7) 9 (16.7) -0.163 0.140
  ILD 12 (80.0) 13 (86.7) 47 (87.0) 0.062 0.576
  Arthritis 4 (26.7) 7 (46.7) 40 (74.1) 0.385 < 0.001
  Myalgia 6 (40.0) 11 (73.3) 24 (44.4) -0.071 0.521
  Myasthenia 6 (40.0) 8 (53.3) 32 (59.3) 0.136 0.218
  Dysphagia 0 0 5 (9.3) 0.183 0.096
  Mechanic hands 4 (26.7) 8 (53.3) 33 (61.1) 0.233 0.033
  Raynaud phenomenon 0 1 (2.6) 10 (15.2) 0.223 0.041
  Gottron sign 9 (60.0) 12 (80.0) 47 (87.3) 0.236 0.031
  Malignancy 1 (6.7) 0 1 (1.9) -0.074 0.504
  Neurologic abnormality 1 (6.7) 0 3 (5.6) 0.028 0.797
Laboratory data
  Elevated WBC 7 (46.7) 10 (66.7) 38 (70.4) 0.162 0.141
  Decreased lymphocyte 8 (53.3) 9 (60.0) 31 (57.4) 0.016 0.887
  Elevated neutrophil 10 (66.7) 11 (73.3) 38 (70.4) 0.013 0.905
  Elevated ESR 7 (46.7) 4 (26.7) 31 (57.4) 0.159 0.151
  Elevated CRP 7 (46.7) 1 (6.7) 24 (44.4) 0.087 0.445
  Decreased albumin 13 (86.7) 10 (66.7) 40 (74.1) -0.058 0.600
  Elevated CK 4 (26.7) 8 (53.3) 34 (63.0) 0.263 0.016
  Elevated LDH 13 (86.7) 10 (66.7) 43 (79.6) 0.002 0.958
  Elevated α-HBD 10 (66.7) 9 (60.0) 47 (87.0) 0.255 0.021

Table 3

Comparison of clinical features and laboratory data in ASS patients with positive anti-Jo-1 antibody only and ASS patients positive for anti-Jo-1 antibody combined with other MAAs/MSAs"

Items Isolated anti-Jo-1 (+)
(n=20)		 Coexistence of anti-Jo-1 (+) and MAAs/MSAs (+)
(n=64)		 t/Z/χ2 P
Clinical features
  Age of onset/years 45.60±10.15 49.94±13.60 -0.102 0.919
  Female 15 (75.0) 49 (76.6) < 0.001 >0.999
  Fever 5 (25.0) 13 (20.3) 0.018 0.894
  Myalgia 5 (25.0) 36 (56.3) 5.956 0.015
  Myasthenia 7 (35.0) 39 (61.0) 4.138 0.042
  Dysphagia 0 5 (7.8) 0.332a
  Gottron sign 15 (75.0) 53 (82.8) 0.203 0.652
  Raynaud phenomenon 2 (10.0) 9 (14.1) 0.008 0.928
  ILD 17 (85.0) 55 (85.9) < 0.001 >0.999
  Mechanic hands 9 (45.0) 36 (56.3) 0.775 0.379
  Arthritis 11 (55.0) 40 (62.5) 0.359 0.549
  Neurologic abnormality 1 (5.0) 3 (4.7) >0.999a
  Malignancy 1 (5.0) 1 (1.6) 0.422a
Laboratory data
  ESR/(mm/h) 15.5 (7.5, 31.5) 22.0 (8.0, 56.0) -1.076 0.282
  Elevated ESR 9 (45.0) 33 (51.6) 0.331 0.565
  CRP/(mg/L) 7.1 (0.5, 12.4) 4.3 (0.6, 32.2) -0.952 0.341
  Elevated CRP 8 (40.0) 24 (37.5) 0.046 0.836
  CK/(U/L) 155.0 (80.0, 756.0) 237.0 (100.0, 1153.0) -0.799 0.425
  Elevated CK 10 (50.0) 36 (56.3) 0.313 0.576

Figure 3

Condition of anti-Jo-1 antibody with anti-Ro-52, anti-PM-Scl 75/100 and ANA in IIM patients The red part represents the anti-Jo-1 antibody-positive samples, the blue part represents the anti-Ro-52 antibody-positive samples, the purple part represents the anti-PM-Scl 75/100 antibody-positive samples, the green part represents the antinuclear antibody-positive samples, and the overlap part represents the patients with two or more positive antibodies at the same time."

1 Tanboon J , Nishino I . Classification of idiopathic inflammatory myopathies: Pathology perspectives[J]. Curr Opin Neurol, 2019, 32 (5): 704- 714.
doi: 10.1097/WCO.0000000000000740
2 Galindo-Feria AS , Horuluoglu B , Lundberg IE . Anti-Jo 1 autoantibodies, from clinic to the bench[J]. Rheumatology and Autoimmnity, 2022, 2 (2): 57- 68.
doi: 10.1002/rai2.12035
3 García-De La Torre I . Clinical usefulness of autoantibodies in idiopathic inflammatory myositis[J]. Front Immunol, 2015, 6, 331.
4 Ceribelli A , De Santis M , Isailovic N , et al. The immune response and the pathogenesis of idiopathic inflammatory myositis: A critical review[J]. Clin Rev Allergy Immunol, 2017, 52 (1): 58- 70.
doi: 10.1007/s12016-016-8527-x
5 Zhan X , Yan W , Wang Y , et al. Clinical features of anti-synthetase syndrome associated interstitial lung disease: A retrospective cohort in China[J]. BMC Pulm Med, 2021, 21 (1): 57.
doi: 10.1186/s12890-021-01399-5
6 Fredi M , Cavazzana I , Quinzanini M , et al. Rare autoantibodies to cellular antigens in systemic lupus erythematosus[J]. Lupus, 2014, 23 (7): 672- 677.
doi: 10.1177/0961203314524850
7 Kumar RR , Jha S , Dhooria A , et al. Anti-Jo-1 syndrome often misdiagnosed as rheumatoid arthritis (for many years): A single-center experience[J]. J Clin Rheumatol, 2021, 27 (4): 150- 155.
doi: 10.1097/RHU.0000000000001234
8 Ishikawa Y , Yukawa N , Ohmura K , et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: A case report and review of the literature[J]. Clin Rheumatol, 2010, 29 (5): 563- 566.
doi: 10.1007/s10067-009-1370-1
9 Eriksson C , Rantapää-Dahlqvist S . Cytokines in relation to autoantibodies before onset of symptoms for systemic lupus erythematosus[J]. Lupus, 2014, 23 (7): 691- 696.
doi: 10.1177/0961203314523869
10 赵娜, 刘颖, 孙小凤, 等. 不同抗氨酰tRNA合成酶抗体阳性的抗合成酶综合征60例临床和影像学相关特征分析[J]. 中华风湿病学杂志, 2019, 23 (5): 320- 325.
11 Adams RA , Fernandes-Cerqueira C , Notarnicola A , et al. Serum-circulating His-tRNA synthetase inhibits organ-targeted immune responses[J]. Cell Mol Immunol, 2021, 18 (6): 1463- 1475.
doi: 10.1038/s41423-019-0331-0
12 Honda M , Shimizu F , Sato R , et al. Jo-1 antibodies from myositis induce complement-dependent cytotoxicity and TREM-1 upregulation in muscle endothelial cells[J]. Neurol Neuroimmunol Neuroinflamm, 2023, 10 (4): e200116.
doi: 10.1212/NXI.0000000000200116
13 Cavagna L , Nuño L , Scirè CA , et al. Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: Results from an international retrospective multicenter study[J]. Medicine (Baltimore), 2015, 94 (32): e1144.
doi: 10.1097/MD.0000000000001144
14 Monti S , Montecucco C , Cavagna L . Clinical spectrum of anti-Jo-1-associated disease[J]. Curr Opin Rheumatol, 2017, 29 (6): 612- 617.
doi: 10.1097/BOR.0000000000000434
15 Lundberg IE , Tjärnlund A , Bottai M , et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups[J]. Ann Rheum Dis, 2017, 76 (12): 1955- 1964.
doi: 10.1136/annrheumdis-2017-211468
16 Solomon J , Swigris JJ , Brown KK . Myositis-related interstitial lung disease and antisynthetase syndrome[J]. J Bras Pneumol, 2011, 37 (1): 100- 109.
doi: 10.1590/S1806-37132011000100015
17 Allenbach Y , Mammen AL , Benveniste O , et al. 224th ENMC international workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016[J]. Neuromuscul Disord, 2018, 28 (1): 87- 99.
doi: 10.1016/j.nmd.2017.09.016
18 Mielnik P , Wiesik-Szewczyk E , Olesinska M , et al. Clinical features and prognosis of patients with idiopathic inflammatory myo-pathies and anti-Jo-1 antibodies[J]. Autoimmunity, 2006, 39 (3): 243- 247.
doi: 10.1080/08916930600623767
19 Aggarwal R , Cassidy E , Fertig N , et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients[J]. Ann Rheum Dis, 2014, 73 (1): 227- 232.
doi: 10.1136/annrheumdis-2012-201800
20 Ge YP , Zhang YL , Shu XM , et al. Clinical characteristics of anti-isoleucyl-tRNA synthetase antibody associated syndrome and comparison with different patient cohorts[J]. Clin Exp Rheumatol, 2022, 40 (3): 625- 630.
doi: 10.55563/clinexprheumatol/v2rbd0
21 Satoh M , Tanaka S , Ceribelli A , et al. A comprehensive overview on myositis-specific antibodies: New and old biomarkers in idiopathic inflammatory myopathy[J]. Clin Rev Allergy Immunol, 2017, 52 (1): 1- 19.
doi: 10.1007/s12016-015-8510-y
22 Liu Y , Luo H , Wang L , et al. Increased serum matrix metalloproteinase-9 levels are associated with anti-Jo1 but not anti-MDA5 in myositis patients[J]. Aging Dis, 2019, 10 (4): 746- 755.
doi: 10.14336/AD.2018.1120
23 Zhao L , Su K , Liu T , et al. Myositis-specific autoantibodies in adults with idiopathic inflammatory myopathy: Correlations with diagnosis and disease activity[J]. Clin Rheumatol, 2021, 40 (3): 1009- 1016.
doi: 10.1007/s10067-020-05273-3
24 Zhang S , Shu X , Tian X , et al. Enhanced formation and impaired degradation of neutrophil extracellular traps in dermatomyositis and polymyositis: A potential contributor to interstitial lung disease complications[J]. Clin Exp Immunol, 2014, 177 (1): 134- 141.
doi: 10.1111/cei.12319
25 Kryštůfková O , Hulejová H , Mann HF , et al. Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis[J]. Arthritis Res Ther, 2018, 20 (1): 158.
doi: 10.1186/s13075-018-1650-8
26 Ascherman DP , Oriss TB , Oddis CV , et al. Critical requirement for professional APCs in eliciting T cell responses to novel fragments of histidyl-tRNA synthetase (Jo-1) in Jo-1 antibody-positive polymyositis[J]. J Immunol, 2002, 169 (12): 7127- 7134.
doi: 10.4049/jimmunol.169.12.7127
27 Oldroyd AGS , Allard AB , Callen JP , et al. A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies[J]. Rheumatology (Oxford), 2021, 60 (6): 2615- 2628.
doi: 10.1093/rheumatology/keab166
28 郑艺明, 郝洪军, 刘怡琳, 等. Ro52抗体与其他肌炎抗体共阳性的相关性研究[J]. 北京大学学报(医学版), 2020, 52 (6): 1088- 1092.
29 Marie I , Hatron PY , Dominique S , et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody[J]. Semin Arthritis Rheum, 2012, 41 (6): 890- 899.
doi: 10.1016/j.semarthrit.2011.09.008
[1] Fang-ning YOU,Liang LUO,Xiang-jun LIU,Xue-wu ZHANG,Chun LI. Analysis of pregnancy outcomes, disease progression, and risk factors in patients with undifferentiated connective tissue disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1045-1052.
[2] LUO Lan,XING Xiao-yan,XIAO Yun-shu,CHEN Ke-yan,ZHU Feng-yun-zhi,ZHANG Xue-wu,LI Yu-hui. Clinical and immunological characteristics of patients with anti-synthetase syndrome complicated with cardiac involvement [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1078-1082.
[3] Shi-xiong WEI,Shu-jia LI,Yi LIU. Clinical characteristics and biological treatment of adult patient with juvenile idiopathic arthritis [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1014-1022.
[4] Hai-hong YAO,Yi-ni WANG,Xia ZHANG,Jin-xia ZHAO,Yuan JIA,Zhao WANG,Zhan-guo LI. Clinical characteristics and treatment outcomes of macrophage activation syndrome in adults: A case series of 67 patients [J]. Journal of Peking University(Health Sciences), 2019, 51(6): 996-1002.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 434 -436 .
[2] . [J]. Journal of Peking University(Health Sciences), 2001, 33(1): 50 -53 .
[3] . [J]. Journal of Peking University(Health Sciences), 2001, 33(6): 540 -544 .
[4] . [J]. Journal of Peking University(Health Sciences), 2002, 34(1): 33 -35 .
[5] . [J]. Journal of Peking University(Health Sciences), 2002, 34(2): 97 -98 .
[6] . [J]. Journal of Peking University(Health Sciences), 2002, 34(2): 140 -143 .
[7] . [J]. Journal of Peking University(Health Sciences), 2010, 42(4): 476 -479 .
[8] . [J]. Journal of Peking University(Health Sciences), 2008, 40(2): 208 -210 .
[9] . [J]. Journal of Peking University(Health Sciences), 2010, 42(5): 520 -525 .
[10] . [J]. Journal of Peking University(Health Sciences), 2011, 43(2): 179 -182 .
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd